We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Open Biosystems Launches GIPZ Lentiviral shRNAmir Library
Product News

Open Biosystems Launches GIPZ Lentiviral shRNAmir Library

Open Biosystems Launches GIPZ Lentiviral shRNAmir Library
Product News

Open Biosystems Launches GIPZ Lentiviral shRNAmir Library


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Open Biosystems Launches GIPZ Lentiviral shRNAmir Library "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Open Biosystems, Inc. has announced the availability of its Expression ArrestT GIPZ lentiviral shRNAmir libraries.

Targeting the entire human genome with multiple shRNAmir constructs per gene, the GIPZ lentiviral shRNAmir library builds on Open Biosystems' RNAi technologies that enable researchers to realize the inherent value of RNAi.

The GIPZ library consists of shRNAmir constructs that have been pre-cloned into the GIPZ lentiviral vector, resulting in an RNAi trigger that features increased knockdown specificity and efficiency.

Open Biosystems' GIPZ shRNAmir is designed to provide researchers and scientists with expanded usability and increased delivery into a range of cell types spanning primary and non-dividing cells.

Most recently, the National Cancer Institute (NCI) selected Open Biosystems to verify the effectiveness of shRNAmir technology in 135 specifically targeted cancer genes.

This award will provide researchers with a validated set of cancer gene targeting reagents and data that can be utilized to better identify and study the specific genes involved in the development of cancer.

"Lentiviral shRNAmir is the most powerful RNAi resource available. Open Biosystems continues to arm the research community with the RNAi tools necessary to propel research efforts to the next level," said Troy Moore, chief technology officer at Open Biosystems.

"It remains our mission to provide commercial and academic researchers with the proven tools and technologies to further genomic research that may lead to advanced diagnostics and treatment options for diseases such as cancer, Alzheimer's, diabetes and others."

Advertisement